Stock market today: Asian stocks mixed ahead of US inflation data
TikTok seeks to reassure U.S. employees ahead of Jan. 19 ban deadline
US won't seek charges in unarmed Black motorist Ronald Greene's fatal 2019 arrest
Euro zone households could increase consumption, ECB chief economist says
Foreigners sold South Korean equities last month by most since early 2020
As fires ravage Los Angeles, Tiger Woods isn't sure what will happen with Riviera tournament
Antetokounmpo gets 50th career triple-double as Bucks win 130-115 to end Kings' 7-game win streak
No 97 Laura Siegemund upsets Olympic champion Zheng Qinwen at the Australian Open
(Reuters) - Paris-based drugmaker Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics, Bloomberg News reported on Thursday citing people familiar with the matter.
Deliberations are ongoing and there is no certainty they will result in an agreement, the report said, adding that Mirati could also attract interest from other suitors.
A Sanofi spokesperson responded to a Reuters' request saying the company does not comment on market rumors. Mirati, whose shares rose 25.48% to $53.83, did not immediately respond to Reuters' request for a comment.
Mirati's lung cancer drug, Krazati, had received the U.S. health regulator's nod in December to treat adults with advanced lung cancer.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
